Multivariable analysis of short- and long-term outcomes for all patients according to transplant platform
| Outcome . | Relative risk (95% CI) . | P . | |
|---|---|---|---|
| sUCBT . | Haplo-Cord . | ||
| Myeloid engraftment | 1 | 2.3 (1.5-3.3) | <.001 |
| Platelet engraftment | 1 | 1.6 (1.2-2.3) | .015 |
| aGVHD, grade II-IV | 1 | 0.5 (0.2-1.1) | .08 |
| cGVHD | 1 | 0.5 (0.3-0.8) | .01 |
| NRM | 1 | 1 (0.6-1.6) | 1 |
| Relapse | 1 | 1.2 (0.7-2.1) | .6 |
| LFS | 1 | 1 (0.7-1.4) | .8 |
| GVHD-free/relapsed-free survival | 1 | 1 (0.8-1.2) | 1 |
| Outcome . | Relative risk (95% CI) . | P . | |
|---|---|---|---|
| sUCBT . | Haplo-Cord . | ||
| Myeloid engraftment | 1 | 2.3 (1.5-3.3) | <.001 |
| Platelet engraftment | 1 | 1.6 (1.2-2.3) | .015 |
| aGVHD, grade II-IV | 1 | 0.5 (0.2-1.1) | .08 |
| cGVHD | 1 | 0.5 (0.3-0.8) | .01 |
| NRM | 1 | 1 (0.6-1.6) | 1 |
| Relapse | 1 | 1.2 (0.7-2.1) | .6 |
| LFS | 1 | 1 (0.7-1.4) | .8 |
| GVHD-free/relapsed-free survival | 1 | 1 (0.8-1.2) | 1 |